Antebor

Quick links to important sections

Antebor

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antebor

Quick Facts

Property Description
Active ingredient Sulfacetamide (often Sulfacetamide sodium)
Form Ophthalmic solution, ointment, cream, lotion
Pharmacological class Antibiotic / Sulfonamide / Anti-bacterial agent
Common use Anti-infective control (topical)
Origin Synthetic

What Type of Medicine is Antebor and What is its Composition?

Antebor is a medicinal preparation whose active substance is Sulfacetamide (often the salt form, Sulfacetamide sodium), classifying it as a synthetic anti-bacterial agent belonging to the sulfonamide class of antibiotics. This compound is a manufactured derivative, establishing it as a synthetic medicine, contrasting it with naturally derived antibiotics. Sulfacetamide is the sole active ingredient, and its chemical identity is verified, positioning it as a dedicated anti-infective tool. Sulfacetamide is recognized for its efficacy against a range of susceptible microorganisms.


In What Forms is Antebor Used?

Sulfacetamide is primarily designed for topical administration, delivering the drug directly to the site of potential infection, particularly the eye and skin. Common dosage forms include the ophthalmic solution (eye drops) and ophthalmic ointment for ocular use, as well as creams and lotions for application to the skin. The drug is available in these topical preparations to maximize local exposure while minimizing systemic effects, with the choice of form designed for safety and efficacy. Antebor's focus on topical ophthalmic and dermal preparations differentiates its practical application from that of other sulfonamides often used in oral or systemic settings.


What is the General Therapeutic Purpose of Sulfacetamide?

The general therapeutic purpose of Antebor is to provide effective anti-infective control by limiting the growth of susceptible bacteria. Sulfonamides are classified as bacteriostatic agents, meaning the medicine works by interfering with the bacteria's ability to create vital nutrients like folic acid. This competitive inhibition prevents the microorganisms from multiplying, which helps manage microbial populations. As an agent for controlling bacterial growth, this type of medicine helps the body suppress the bacterial population, giving the immune system time to clear the remaining infection, making it a reliable component in localized infection management.

Regulatory References

  1. FDA Sulfacetamide Ophthalmic Solution Label
  2. FDA Drug Label for Sulfacetamide
  3. FDA Drug Label for Sulfacetamide Sodium

What side effects are possible with Antebor?

Possible Side Effects and Safety Information

The safety profile of Antebor (Sulfacetamide) is characterized by its localized administration and the potential for systemic effects inherent to the sulfonamide class of antibiotics, as documented in regulatory labeling.

Adverse Reactions and Class Risks

Adverse reactions are primarily local effects at the site of application. The most frequently reported reactions are transient stinging or burning and local irritation or mild eye redness (conjunctival hyperemia). Less commonly reported effects include non-specific conjunctivitis, allergic reactions, and the potential for secondary infections, which may involve the overgrowth of non-susceptible organisms, including fungi, particularly with prolonged use.

While rare with topical use, the labeling carries explicit warnings for severe, potentially fatal systemic reactions associated with the sulfonamide drug class. These serious adverse events include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), fulminant hepatic necrosis, and severe blood dyscrasias such as aplastic anemia and agranulocytosis. The risk of these systemic effects is greater if the medicine is applied to large areas of compromised skin, such as severely burned, abraded, or infected areas, due to increased systemic absorption.


Safety Constraints and Special Populations

Hypersensitivity to any sulfonamide is a contraindication, and cross-sensitivity between different sulfonamide agents is documented. Furthermore, safety and effectiveness have not been established in infants under the age of two months. Regulatory notes advise caution in nursing mothers due to the potential risk of kernicterus associated with systemically absorbed sulfonamides. Sulfacetamide preparations are also noted to be incompatible with silver preparations.

Overdose and Emergency Response

The official overdose profile for Antebor (Sulfacetamide), a topical sulfonamide antibiotic, addresses the risk of systemic toxicity that may occur following accidental oral ingestion or excessive absorption through compromised skin.

Documented Overdose Manifestations

Documented presentations for large oral overdosage include gastrointestinal effects such as nausea and vomiting. More critically, overexposure may result in acute renal manifestations, specifically crystalluria and hematuria, which are signs of sulfa crystal precipitation in the urinary tract, potentially leading to renal shutdown.

Regulatory documents emphasize the risk of rare, life-threatening complications associated with the sulfonamide class, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and serious blood dyscrasias such as aplastic anemia or fulminant hepatic necrosis.

When to Seek Immediate Medical Help

Official regulatory instructions mandate that at the first sign of a serious reaction, skin rash, or hypersensitivity, the preparation must be immediately discontinued. In the event of suspected overdosage or accidental ingestion, emergency treatment should be started immediately. Patients are required to seek medical help right away, call emergency services, or contact a Poison Control Center. Management of overdosage is primarily symptomatic and supportive, as no specific antidote is officially documented.

Therapeutic Uses of Antebor

What Antebor Treats: Main Uses and Benefits

Antebor is a medication generally used to help manage symptoms across a range of conditions characterized by periods of heightened symptoms affecting mood and physiological balance.

The primary therapeutic areas for this class of medicine include major depressive disorder, anxiety, and other relevant mental health conditions.

This medication is commonly used to help with symptoms related to physical discomfort, symptoms related to systemic imbalance, and other manifestations that interfere with daily comfort. Specifically, it is considered relevant for easing symptoms that interfere with daily functioning across conditions presenting with acute episodes, such as Major Depressive Disorder, Generalized Anxiety Disorder, Panic Disorder, Obsessive-Compulsive Disorder, and Post-Traumatic Stress Disorder.

“The supportive relief offered may help patients cope more steadily with symptom fluctuations.”

The medication may be used during phases when symptoms become more noticeable, and may assist with easing the overall symptom load. It assists with maintaining functional stability and contributes to easing discomfort during symptomatic periods.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus overview of antidepressants

Eligibility and Restrictions for Use

The eligibility profile for Antebor (topical Sulfacetamide) is strictly defined by regulatory documents, establishing clear limitations on its use.

Eligibility Scope Summary of Official Rules
Contraindicated Populations Individuals with a known hypersensitivity to sulfonamides (sulfa drugs) or any component of the preparation are absolutely contraindicated. Use of certain dermal forms is also prohibited in patients with kidney disease or impaired renal function.
Age-Related Eligibility Use of the ophthalmic solution is not established in infants under two months of age. For most dermal preparations, safety and effectiveness are not established in children under 12 years of age.
Pregnancy/Lactation Status Pregnancy use is restricted (Category C), permitted only if the potential benefit justifies the potential risk. For lactation, a decision to discontinue the drug or discontinue nursing is required due to absorption concerns.
Use Restrictions Caution should be employed when the medicine is applied to large, abraded, or severely burned areas of the skin due to the possibility of increased systemic absorption.

These eligibility rules establish mandatory exclusions based on known allergies and certain comorbidities. Further restrictions govern use in sensitive populations, such as infants and pregnant or nursing mothers, where specific risk-benefit evaluations are required, preventing general use without labeled constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for topical Sulfacetamide (Antebor) as detailed in government regulatory labeling. The primary route of topical administration significantly limits systemic absorption, resulting in a distinct and restricted interaction profile compared to orally administered sulfonamides.

Documented Interaction Patterns

Interaction Type Interacting Substance Official Regulatory Statement
Formal Incompatibility Silver preparations Co-administration is formally documented as an incompatibility and is prohibited.
Antagonistic Effect Para-aminobenzoic acid (PABA) Effectiveness is subject to reduction by PABA present in purulent exudates at the site of administration.

Co-administration with silver preparations is categorized in regulatory documents as a contraindicated or prohibited combination due to the documented chemical incompatibility. The local antagonistic interaction with PABA is a specific constraint tied to the infection context, where the presence of PABA reduces the medicine's anti-bacterial activity.

Official prescribing information for this topical sulfonamide does not document systemic drug-drug interactions involving major metabolic pathways (such as CYP enzymes) or drug transporters. Similarly, no specific interaction statements are documented regarding food, alcohol, or common herbal supplements.

Mechanism of Action

Targeted Inhibition of Microbial Metabolism

The mechanism of action centers on competitive inhibition of the bacterial enzyme Dihydropteroate synthase (DHPS). The active substance structurally mimics the enzyme's natural substrate, Para-aminobenzoic acid (PABA), thereby blocking the active site of DHPS and halting the first critical step in the microbial folic acid synthesis pathway. This highly specific action targets a metabolic process essential only to susceptible bacteria.

Arrest of Replication and Proliferation

The block in folic acid synthesis leads to the rapid depletion of necessary cofactors, such as tetrahydrofolate, within the bacterial cell. Since these cofactors are vital for the creation of DNA, RNA, and proteins, their depletion results in the inability of the bacterial population to synthesize new genetic material and divide. The functional consequence is a bacteriostatic effect, meaning the microbial population's proliferation is arrested.

Mechanistic Constraint and Dependence

The action is fundamentally growth-inhibiting, not cell-killing. This mechanistic constraint indicates that the complete physiological resolution of the infection is dependent on the host's clearance mechanisms. Furthermore, the competitive nature of the inhibition means that resistance may emerge if bacteria genetically mutate the DHPS target or significantly overproduce PABA.

Dosage and Administration Information

How to use Antebor

Antebor, which contains the active ingredient Sulfacetamide sodium, is administered via the topical route, with specific instructions for application to the eyes (ophthalmic) and the skin (cutaneous). The preparation used—ophthalmic solution, ophthalmic ointment, cream, or lotion—determines the precise method and frequency of use.

Topical Ophthalmic Administration

For ophthalmic use, the solution form is used by instilling one or two drops, typically at a frequency of every two to three hours during the initial phase of the course. The ointment form is applied as an approximate 1/2-inch ribbon to the conjunctival sac, with applications generally scheduled every three to four hours and at bedtime. Treatment is structured as a short-term course, usually lasting seven to ten days, and includes a tapering protocol where the time interval between doses is increased as the condition improves.

Topical Dermal Administration

Dermal forms, such as creams and lotions, require the application of a thin layer to the affected area, usually twice daily (morning and evening) after the skin has been thoroughly cleansed.

Usage Precautions

It is essential to maintain strict route separation: ophthalmic products are not for injection, and dermal products are not for ophthalmic use. Furthermore, administration requires adherence to non-contamination principles, advising that the container tip should not touch the eye or skin surface during application. The safety and effectiveness of the ophthalmic solution are not established for children under two months of age.

Recent Clinical Evidence

Research evidence / Overview of Studies for Antebor (Sulfacetamide)


Evidence for Use in Superficial Ophthalmic Infections

Research on the ophthalmic solution and ointment formulations of Antebor was studied in research contexts involving temporary irritation or acute issues affecting the surface of the eye, such as bacterial infections. The studies primarily focused on regulatory standards and evaluations to confirm equivalence among different formulations. Researchers monitored outcomes describing episodic or acute changes, such as the visible status of infection signs and the microbiological status of the bacteria. The populations evaluated in this research included adults and children as young as two months old.

Clinical studies described patterns of signs and symptoms recorded during short treatment periods, and regulatory data reported measurements of bacterial susceptibility to the medication. However, the evidence is limited regarding extended outcomes. Data concerning use beyond the standard, brief treatment course are not fully established. Ongoing research is necessary to monitor whether bacteria develop resistance over time, and comparative evidence against the newest available ophthalmic treatments is limited.


Evidence for Use in Dermatological Conditions

This section outlines research for the topical formulations of Antebor was evaluated in patients with conditions characterized by fluctuating or episodic manifestations on the skin. This evidence primarily consists of trials where Antebor was often used in combination with sulfur.

Evidence for Acne Vulgaris

Acne research explored short-term symptom changes in adolescents and adults diagnosed with mild to moderate inflammatory lesions. The studies were often Randomized Controlled Trials (RCTs) which explored the fixed-dose combination product against an inactive control substance. Researchers measured outcomes linked to inflammatory or irritative states over defined time intervals, typically between 8 and 12 weeks, focusing on the percent change in inflammatory lesion counts.

Evidence for Papulopustular Rosacea

Research in this area was studied for a condition marked by functional limitations, often using the combination formulation. The studies monitored outcomes related to inflammatory or irritative states, such as the count of inflammatory lesions and the grading of facial redness (erythema) in adults. Findings describe patterns observed in the measurement of papules and pustules and the measurement of facial redness severity over typical short study durations.


Long-Term Studies and Follow-up Duration

The majority of evidence is derived from research exploring short-term symptom changes. Studies help show what has been observed so far, but the follow-up durations were limited. This means that data concerning extended outcomes and the persistence of findings are not fully established, particularly for the dermatological indications. Research does not provide extensive context on what happens after individuals stop using the product or if it is studied continuously over many months.


What Research Gaps and Uncertainties Remain

Several key research gaps have been identified. For the dermatological combination product, the independent focus of Antebor alone is uncertain because most published studies examined the fixed-dose combination with sulfur. Comparative evidence is lacking against newer treatment agents, and evidence quality varies across studies, with some older trials posing a higher risk of bias. Overall, the available data are still emerging and certain extended outcomes or results in specific subgroups remain insufficient.

Key Studies & References

  1. Combination Sodium Sulfacetamide 10% and Sulfur 5% Cream With Sunscreens Versus Metronidazole 0.75% Cream for Rosacea (Comparative Trial)
  2. The Use of Sodium Sulfacetamide in Dermatology (Review for Acne, Rosacea, and Seborrheic Dermatitis)

Frequently Asked Questions (FAQ)

Common questions about Antebor (FAQ)

Q: Can Antebor be taken long-term, or is it only for short courses?

Antebor is primarily intended for short-term use. Official guidance for ophthalmic application, for example, is typically structured as a course lasting seven to ten days. The safety and effectiveness of using Antebor beyond the standard short-term course are not established in the official prescribing information.


Q: Are there any side effects of Antebor that can be delayed?

While rare with topical use, regulatory warnings associated with the sulfonamide class of antibiotics do note the potential for severe systemic reactions, such as Stevens-Johnson Syndrome or aplastic anemia. These potentially severe events may occur at any point, though their occurrence is considered rare with typical topical application.


Q: Is it safe to drink coffee or tea while taking Antebor?

Official prescribing information does not document specific interaction statements regarding the consumption of food, alcohol, common herbal supplements, or beverages like coffee or tea. The official product information does not indicate specific restrictions on coffee or tea consumption.


Q: Can Antebor cause stomach upset or digestive issues?

Gastrointestinal side effects, such as stomach upset or digestive issues, are not listed among the most frequently reported adverse reactions for topical Antebor. The most common side effects reported are typically localized, such as transient stinging or burning at the site of application.


Q: Is it normal to feel tired or dizzy when starting Antebor?

Fatigue and dizziness are not listed among the commonly reported side effects in the product label. However, in very rare cases, the systemic reactions associated with sulfonamides can include blood dyscrasias, where unusual weakness or fatigue may be observed.


Q: How long does Antebor stay in your system after you stop taking it?

Antebor is designed for topical use, which results in limited absorption into the body. If absorbed systemically, the active ingredient is generally cleared from the bloodstream within a day. No specific time for total elimination is provided in the general product information.


Q: Are there any natural remedies that shouldn't be combined with Antebor?

The official product labeling does not document specific interaction statements concerning common herbal supplements or natural remedies. This is consistent with the drug’s intended topical application.


Q: Can Antebor be crushed or split if someone has trouble swallowing pills?

Antebor is available only in topical forms (solutions, ointments, creams, or lotions) for application to the eye or skin. It is not formulated as an oral pill that can be crushed, split, or swallowed.


Q: Does Antebor require any special monitoring or blood tests?

Regulatory documents indicate that laboratory determinations and appropriate observations are necessary if the medicine is applied to large areas of compromised skin, such as severely burned or abraded areas. This is due to the potential for increased systemic absorption in those cases.


Q: Can Antebor be used by people with existing kidney problems?

Use of certain dermal forms of Antebor is contraindicated (prohibited) in patients who have kidney disease or impaired renal function. This restriction is clearly defined in the official warnings and contraindications for the drug.


Q: Is it important to take Antebor at the exact same time every day?

For the initial treatment phase, Antebor is often prescribed for highly frequent application, such as every two to three hours for ophthalmic use. Following the prescribed interval helps maintain the concentration of the medicine at the application site.


Q: How effective is Antebor based on patient reviews and studies?

Research studies have measured the medicine’s ability to change or improve symptoms over a short period, such as the visible status of infection signs and the percent change in inflammatory lesion counts. Official information reports effectiveness based on these measurable outcomes observed during regulated study periods.


Q: Can Antebor affect a person's ability to drive or operate machinery?

Warnings associated with the product recommend caution regarding driving or operating machinery until the individual knows how the medicine affects them. This is a general safety measure that accounts for the rare possibility of systemic effects that could impair concentration or coordination.


Q: What are the signs of an allergic reaction to Antebor?

Signs of an allergic reaction to Antebor or the sulfonamide class can include a sudden rash, hives, itching, or swelling of the face, lips, or throat. Serious reactions may also include difficulty breathing (wheezing), tightness in the chest or throat, or the development of severe skin conditions like blistering or peeling.


Q: Is Antebor available over-the-counter in any country?

In the United States, the product labeling contains the designation 'Rx Only'. This designation means the medicine is regulated to be dispensed only upon presentation of a prescription.

How should Antebor be stored and disposed of?

The official prescribing information for Antebor (Sulfacetamide) defines strict requirements for storage, handling, and disposal.

Required Storage Conditions

Antebor must be kept at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F), and must not be frozen [Source: FDA DailyMed / NIH MedlinePlus]. The product must be stored in its original container, kept tightly closed, and protected from light to maintain stability.

For safety, the medicine must be stored out of the sight and reach of children.

Disposal and Stability

The product should be discarded if it shows any darkening in color or after passing the labeled expiration date. Unused or expired Antebor must not be disposed of in household trash or wastewater. Instead, regulatory guidelines recommend utilizing a drug take-back program or following specific local environmental disposal instructions [Source: NIH MedlinePlus].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antebor found in:

A-Z Index: